Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia

Journal of Psychopharmacology

Volumn 24, Issue 7, 2010, Pages 1031-1035

  Tenback, D E ^a,b   Van Harten, P N ^a,c   Slooff, C J ^c,d   Van Os, J ^e,f  

^a Symfora Group Psychiatric Center   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Mental Health Centre Drenthe   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Epidemiology; Extrapyramidal; Longitudinal; Schizophrenia; Tardive dyskinesia

Indexed keywords

ADULT; ARTICLE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; COHORT STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77953738797     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106306     Document Type: Article

References (30)

1. Ballesteros, J., Gonzalez-Pinto, A., Bulbena, A. (2000) Tardive dyskinesia associated with higher mortality in psychiatric patients results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 20: 188-194.
2. Bergen, JA, Eyland, EA, Campbell, JA, Jenkings, P., Kellehear, K., Richards, A., et al. (1989) The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 154: 523-528.
3. Chakos, MH, Alvir, JM, Woerner, MG, Koreen, A., Geisler, S., Mayerhoff, D., et al. (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53: 313-319.
4. Chatterjee, A., Chakos, M., Koreen, A., Geisler, S., Sheitman, B., Woerner, M., et al. (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152: 1724-1729.
5. Correll, CU, Leucht, S., Kane, JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics a systematic review of 1-year studies. Am J Psychiatry 161: 414-425.
6. Davis, KL, Kahn, RS, Ko, G., Davidson, M. (1991) Dopamine in schizophrenia a review and reconceptualization. Am J Psychiatry 148: 1474-1486.
7. Emsley, R., Turner, HJ, Schronen, J., Botha, K., Smit, R., Oosthuizen, PP (2004) A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65: 696-701.
8. Fenton, WS (2000) Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 61 (Suppl. 4). 10-14.
9. Fernandez, HH, Krupp, B., Friedman, JH (2001) The course of tardive dyskinesia and parkinsonism in psychiatric inpatients 14-year follow-up. Neurology 56 (6). 805-807.
10. Geddes, J., Freemantle, N., Harrison, P., Bebbington, P. (2000) Atypical antipsychotics in the treatment of schizophrenia systematic overview and meta-regression analysis. BMJ 321: 1371-1376.
11. Gerlach, J. (1977) The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry 134: 781-784.
12. Glazer, WM, Morgenstern, H., Doucette, JT (1991) The prediction of chronic persistent versus intermittent tardive dyskinesia A retrospective follow-up study. Br J Psychiatry 158: 822-828.
13. Haro, JM, Edgell, ET, Jones, PB, Alonso, J., Gavart, S., Gregor, KJ, et al. (2003) The European Schizophrenia Outpatient Health Outcomes (SOHO) study rationale, methods and recruitment. Acta Psychiatr Scand 107: 222-232.
14. Hirvonen, J., van Erp, TG, Huttunen, J., Aalto, S., Nagren, K., Huttunen, M., et al. (2005) Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62: 371-378.
15. Honer, WG, Kopala, LC, Rabinowitz, J. (2005) Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol 19: 277-285.
16. Kane, JM, Woerner, M., Borenstein, M., Wegner, J., Lieberman, J. (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22: 254-258.
17. Kane, JM, Woerner, M., Weinhold, P., Wegner, J., Kinon, B., Borenstein, M. (1984) Incidence of tardive dyskinesia five-year data from a prospective study. Psychopharmacol Bull 20: 387-389. (Pubitemid 14090996)
18. Koning, JPF, Tenback, DE, van Os, J., Aleman, A., Kahn, RS, van Harten, PN (2008) Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull Nov 5 (Epub ahead of print).
19. Koshino, Y., Wada, Y., Isaki, K., Kurata, K. (1991) A long-term outcome study of tardive dyskinesia in patients on antipsychotic medication. Clin Neuropharmacol 14: 537-546.
20. Morgenstern, H., Glazer, WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 50: 723-733.
21. Murray, RM, Van Os, J. (1998) Predictors of outcome in schizophrenia. J Clin Psychopharmacol 18 (2 Suppl. 1). 2S - 4S.
22. Sachdev, P. (2004) Early extrapyramidal side-effects as risk factors for later tardive dyskinesia a prospective study. Aust N Z J Psychiatry 38: 445-449.
23. Schooler, NR, Kane, JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486-487.
24. Schroder, J., Silvestri, S., Bubeck, B., Karr, M., Demisch, S., Scherrer, S., et al. (1998) D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Biol Psychiatry 43: 660-665.
25. Seeman, P. (2002) Atypical antipsychotics mechanism of action. Can J Psychiatry 47: 27-38.
26. Tenback, DE, van Harten, PN, Slooff, CJ, Belger, MA, van Os, J. (2005) Effects of Antipsychotic Treatment on Tardive Dyskinesia A 6-Month Evaluation of Patients From the European Schizophrenia Outpatient Health Outcomes (SOHO). Study J Clin Psychiatry 66: 1130-1133.
27. Tenback, DE, van Harten, PN, Slooff, CJ, van Os, J. (2006) Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology 31: 1832-1837.
28. Tenback, DE, van Harten, PN, Slooff, CJ, van Os, J. (2007) Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry 48: 436-440.
29. Weiden, PJ, Mann, JJ, Haas, G., Mattson, M., Frances, A. (1987) Clinical nonrecognition of neuroleptic-induced movement disorders a cautionary study. Am J Psychiatry 144: 1148-1153.
30. Yassa, R., Nair, NP (1992) A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand 86: 262-266.